EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Response to COVID‐19 vaccination in patients on cancer therapy: Analysis in a SARS‐CoV‐2‐naïve population

George Cavic iD, Andrew A Almonte, Sarah M Hicks, Teresa Neeman, Jo-Wai Wang, Sue Brew, Philip Y Choi, Ian Cockburn, Elizabeth E Gardiner, Desmond Yip, Aude M Fahrer, Yada Kanjanapan

Asia-Pacific Journal of Clinical Oncology · 2024

DOI: 10.1111/ajco.14047 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Asia-Pacific Journal of Clinical Oncology, 2024. Verfasst von George Cavic und 11 weiteren Autor:innen. Beteiligte Einrichtung: Research School of Biology, Australian National University, Canberra, Australia. Hauptthemen laut MEDLINE: COVID-19, Neoplasms, COVID-19 Vaccines, SARS-CoV-2. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Australian Government Research Training Program Scholarship, Canberra Hospital Radiation Oncology Private Practice Fund, The Canberra Hospital Private Practice Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Cancer patients have increased morbidity and mortality from COVID‐19, but may respond poorly to vaccination. The Evaluation of COVID‐19 Vaccination Efficacy and Rare Events in Solid Tumors (EVEREST) study, comparing seropositivity between cancer patients and healthy controls in a low SARS‐CoV‐2 community‐transmission setting, allows determination of vaccine response with minimal interference from infection.

Methods

Solid tumor patients from The Canberra Hospital, Canberra, Australia, and healthy controls who received COVID‐19 vaccination between March 2021 and January 2022 were included. Blood samples were collected at baseline, pre‐second vaccine dose and at 1, 3 (primary endpoint), and 6 months post‐second dose. SARS‐CoV‐2 anti‐spike‐RBD (S‐RBD) and anti‐nucleocapsid IgG antibodies were measured.

Results

Ninety‐six solid tumor patients and 20 healthy controls were enrolled, with median age 62 years, and 60% were female. Participants received either AZD1222 (65%) or BNT162b2 (35%) COVID‐19 vaccines. Seropositivity 3 months post vaccination was 87% (76/87) in patients and 100% (20/20) in controls ( p = .12). Seropositivity was observed in 84% of patients on chemotherapy, 80% on immunotherapy, and 96% on targeted therapy (differences not satistically significant). Seropositivity in cancer patients increased from 40% (6/15) after first dose, to 95% (35/37) 1 month after second dose, then dropped to 87% (76/87) 3 months after second dose.

Conclusion

Most patients and all controls became seropositive after two vaccine doses. Antibody concentrations and seropositivity showed a decrease between 1 and 3 months post vaccination, highlighting need for booster vaccinations. SARS‐CoV‐2 infection amplifies S‐RBD antibody responses; however, cannot be adequately identified using nucleocapsid serology. This underlines the value of our COVID‐naïve population in studying vaccine immunogenicity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19NeoplasmsCOVID-19 VaccinesSARS-CoV-2Antibodies, ViralBNT162 VaccineHumansFemaleMaleMiddle AgedAgedAdultVaccinationAged, 80 and overCase-Control StudiesAustralia

Stichwörter der Autor:innen

COVID‐19 vaccineSARS‐CoV‐2seroconversionserologysolid tumor

Substanzen

COVID-19 VaccinesAntibodies, ViralBNT162 Vaccine

Autor:innen und Institutionen

  • Research School of Biology, Australian National University, Canberra, Australia.
  • John Curtin School of Medical Research, Australian National University, Canberra, Australia.
  • Biological Data Science Institute, Australian National University, Canberra, Australia.
  • Medical Oncology Clinical Trials Unit, The Canberra Hospital, Canberra, Australia.
  • Department of Medical Oncology, The Canberra Hospital, Canberra, Australia.
  • ANU Medical School, Australian National University, Canberra, Australia.

ORCID-Profile: George Cavic

Förderung

  • Australian Government Research Training Program Scholarship
  • Canberra Hospital Radiation Oncology Private Practice Fund
  • The Canberra Hospital Private Practice Fund
  • John James Foundation

Zitieren

APA

Cavic, G., Almonte, A. A., Hicks, S. M., Neeman, T., Wang, J. W., Brew, S., Choi, P. Y., Cockburn, I., Gardiner, E. E., Yip, D., Fahrer, A. M., & Kanjanapan, Y. (2024). Response to COVID‐19 vaccination in patients on cancer therapy: Analysis in a SARS‐CoV‐2‐naïve population. Asia-Pacific Journal of Clinical Oncology. https://doi.org/10.1111/ajco.14047

Vancouver

Cavic G, Almonte AA, Hicks SM, Neeman T, Wang JW, Brew S, et al. Response to COVID‐19 vaccination in patients on cancer therapy: Analysis in a SARS‐CoV‐2‐naïve population. Asia-Pacific Journal of Clinical Oncology. 2024. doi:10.1111/ajco.14047

BibTeX
@article{Cavic2024,
  author = {Cavic, George and Almonte, Andrew A and Hicks, Sarah M and Neeman, Teresa and Wang, Jo-Wai and Brew, Sue and Choi, Philip Y and Cockburn, Ian and Gardiner, Elizabeth E and Yip, Desmond and Fahrer, Aude M and Kanjanapan, Yada},
  title = {Response to COVID‐19 vaccination in patients on cancer therapy: Analysis in a SARS‐CoV‐2‐naïve population},
  journal = {Asia-Pacific Journal of Clinical Oncology},
  year = {2024},
  doi = {10.1111/ajco.14047}
}
Kostenlos starten →